Literature DB >> 25798740

Metabolic disposition of the anti-cancer agent [(14)C]laromustine in male rats.

Ala F Nassar1, Adam Wisnewski, Ivan King.   

Abstract

1. Laromustine (VNP40101M, also known as Cloretazine) is a novel sulfonylhydrazine alkylating (anticancer) agent. This article describes the use of quantitative whole-body autoradiography (QWBA) and mass balance to study the tissue distribution, the excretion mass balance and pharmacokinetics after intravenous administration of [(14)C]VNP40101M to rats. A single 10 mg/kg IV bolus dose of [(14)C]VNP40101M was given to rats. 2. The recovery of radioactivity from the Group 1 animals over a 7-day period was an average of 92.1% of the administered dose, which was accounted for in the excreta and carcass. Most of the radioactivity was eliminated within 48 h via urine (48%), with less excreted in feces (5%) and expired air accounted for (11%). The plasma half-life of [(14)C]laromustine was approximately 62 min and the peak plasma concentration (Cmax) averaged 8.3 μg/mL. 3. The QWBA study indicated that the drug-derived radioactivity was widely distributed to tissues through 7 days post-dose after a single 10 mg/kg IV bolus dose of [(14)C]VNP40101M to male pigmented Long-Evans rats. The maximum concentrations were observed at 0.5 or 1 h post-dose for majority tissues (28 of 42). The highest concentrations of radioactivity were found in the small intestine contents at 0.5 h (112.137 µg equiv/g), urinary bladder contents at 3 h (89.636 µg equiv/g) and probably reflect excretion of drug and metabolites. The highest concentrations in specific organs were found in the renal cortex at 1 h (28.582 µg equiv/g), small intestine at 3 h (16.946 µg equiv/g), Harderian gland at 3 h (12.332 µg equiv/g) and pancreas at 3 h (12.635 µg equiv/g). Concentrations in the cerebrum (1.978 µg equiv/g), cerebellum (2.109 µg equiv/g), medulla (1.797 µg equiv/g) and spinal cord (1.510 µg equiv/g) were maximal at 0.5 h post-dose and persisted for 7 days. 4. The predicted total body and target organ exposures for humans given a single 100 µCi IV dose of [(14)C]VNP40101M were well within the medical guidelines for maximum radioactivity exposures in human subjects.

Entities:  

Keywords:  Anti-cancer agent; mass balance; quantitative whole-body autoradiography

Mesh:

Substances:

Year:  2015        PMID: 25798740      PMCID: PMC4681490          DOI: 10.3109/00498254.2015.1016475

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  12 in total

1.  Tissue distribution and elimination of [14C]apixaban in rats.

Authors:  Lifei Wang; Kan He; Brad Maxwell; Scott J Grossman; Larry M Tremaine; W Griffith Humphreys; Donglu Zhang
Journal:  Drug Metab Dispos       Date:  2010-11-11       Impact factor: 3.922

2.  Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats.

Authors:  Y H Park; B H Jung; B C Chung; J Park; C Mitoma
Journal:  Drug Metab Dispos       Date:  1997-09       Impact factor: 3.922

3.  Biodistribution of radiolabeled ethanol in rodents.

Authors:  Andrew N Gifford; Mel Pilar Espaillat; S John Gatley
Journal:  Drug Metab Dispos       Date:  2008-06-19       Impact factor: 3.922

4.  1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.

Authors:  R A Finch; K Shyam; P G Penketh; A C Sartorelli
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  Investigation of figopitant and its metabolites in rat tissue by combining whole-body autoradiography with liquid extraction surface analysis mass spectrometry.

Authors:  Simone Schadt; Susanne Kallbach; Reinaldo Almeida; Jan Sandel
Journal:  Drug Metab Dispos       Date:  2011-12-19       Impact factor: 3.922

6.  Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M).

Authors:  A-E F Nassar; I King; J Du
Journal:  Chem Res Toxicol       Date:  2011-03-25       Impact factor: 3.739

7.  The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.

Authors:  Raymond P Baumann; Helen A Seow; Krishnamurthy Shyam; Philip G Penketh; Alan C Sartorelli
Journal:  Oncol Res       Date:  2005       Impact factor: 5.574

8.  Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.

Authors:  Jan Scicinski; Bryan Oronsky; Michael Taylor; Gang Luo; Timothy Musick; Joseph Marini; Christopher M Adams; William L Fitch
Journal:  Drug Metab Dispos       Date:  2012-06-14       Impact factor: 3.922

9.  A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.

Authors:  Francis Giles; Deborah Thomas; Guillermo Garcia-Manero; Stefan Faderl; Jorge Cortes; Srdan Verstovsek; Alessandra Ferrajoli; Sima Jeha; Miloslav Beran; Charles Koller; Michael Andreeff; Ann Cahill; Caroline Clairmont; Mario Sznol; Hagop Kantarjian
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

10.  1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.

Authors:  P G Penketh; K Shyam; R P Baumann; J S Remack; T P Brent; A C Sartorelli
Journal:  Cancer Chemother Pharmacol       Date:  2003-12-24       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.